OKYO
Price
$1.55
Change
-$0.14 (-8.28%)
Updated
Jul 13 closing price
Capitalization
81.61M
50 days until earnings call
Intraday BUY SELL Signals
RXRX
Price
$3.30
Change
-$0.26 (-7.30%)
Updated
Jul 13 closing price
Capitalization
1.75B
28 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

OKYO vs RXRX

OKYO vs RXRX Comparison Chart in %
View a ticker or compare two or three
VS
OKYO vs. RXRX commentary
Jul 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OKYO is a Buy and RXRX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 14, 2026
Stock price -- (OKYO: $1.55 vs. RXRX: $3.30)
Brand notoriety: OKYO and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: OKYO: 237% vs. RXRX: 94%
Market capitalization -- OKYO: $81.61M vs. RXRX: $1.75B
OKYO [@Biotechnology] is valued at $81.61M. RXRX’s [@Biotechnology] market capitalization is $1.75B. The market cap for tickers in the [@Biotechnology] industry ranges from $121.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

OKYO’s FA Score shows that 0 FA rating(s) are green whileRXRX’s FA Score has 1 green FA rating(s).

  • OKYO’s FA Score: 0 green, 5 red.
  • RXRX’s FA Score: 1 green, 4 red.
According to our system of comparison, RXRX is a better buy in the long-term than OKYO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

OKYO’s TA Score shows that 4 TA indicator(s) are bullish while RXRX’s TA Score has 3 bullish TA indicator(s).

  • OKYO’s TA Score: 4 bullish, 6 bearish.
  • RXRX’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, OKYO is a better buy in the short-term than RXRX.

Price Growth

OKYO (@Biotechnology) experienced а -3.73% price change this week, while RXRX (@Biotechnology) price change was -16.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.21%. For the same industry, the average monthly price growth was +7.25%, and the average quarterly price growth was +1806.27%.

Reported Earning Dates

OKYO is expected to report earnings on Sep 02, 2026.

RXRX is expected to report earnings on Aug 11, 2026.

Industries' Descriptions

@Biotechnology (-3.21% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($1.75B) has a higher market cap than OKYO($81.6M). RXRX YTD gains are higher at: -19.315 vs. OKYO (-25.121).
OKYORXRXOKYO / RXRX
Capitalization81.6M1.75B5%
EBITDAN/A-478.66M-
Gain YTD-25.121-19.315130%
P/E RatioN/AN/A-
RevenueN/A65.7M-
Total CashN/A654M-
Total DebtN/A72.4M-
TECHNICAL ANALYSIS
Technical Analysis
OKYORXRX
RSI
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
84%
MACD
ODDS (%)
Bullish Trend 1 day ago
72%
Bearish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
65%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 4 days ago
87%
Bullish Trend 18 days ago
83%
Declines
ODDS (%)
Bearish Trend 19 days ago
86%
Bearish Trend 1 day ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
88%
Aroon
ODDS (%)
Bullish Trend 5 days ago
90%
Bullish Trend 1 day ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
OKYO
Daily Signal:
Gain/Loss:
RXRX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AIECX18.34N/A
N/A
Invesco EQV International Equity C
RIGKX18.23N/A
N/A
Victory RS International R
MITDX39.49N/A
N/A
MFS Massachusetts Investors Tr R4
SCAYX12.75N/A
N/A
Invesco Income Advantage U.S. Fund Y
FAPJX14.57N/A
N/A
Fidelity Advisor Healthy Future A

OKYO and

Correlation & Price change

A.I.dvisor tells us that OKYO and XRTX have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that OKYO and XRTX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OKYO
1D Price
Change %
OKYO100%
-8.28%
XRTX - OKYO
30%
Poorly correlated
-0.98%
FDMT - OKYO
30%
Poorly correlated
-8.20%
RXRX - OKYO
29%
Poorly correlated
-7.30%
IMUX - OKYO
27%
Poorly correlated
-0.88%
IRON - OKYO
27%
Poorly correlated
-0.80%
More

RXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RXRX has been loosely correlated with ABCL. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if RXRX jumps, then ABCL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RXRX
1D Price
Change %
RXRX100%
-7.30%
ABCL - RXRX
63%
Loosely correlated
-4.12%
CRSP - RXRX
60%
Loosely correlated
-5.10%
PRME - RXRX
60%
Loosely correlated
-7.01%
ABSI - RXRX
57%
Loosely correlated
-3.68%
BEAM - RXRX
55%
Loosely correlated
-5.14%
More